Having invested $2.5 billion and made $5 billion worth of exits across two decades, ChrysCapital has emerged as one of the largest homegrown private equity firms in India. In April, the PE firm and its investors bought 10% stake in Mankind Pharma Ltd for $350 million. Managing partner Kunal Shroff spoke about how ChrysCapital clinched the Mankind Pharma deal at the last minute and investment opportunities that have opened up in the distressed space. Edited excerpts from an interview:
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
